Global Chronic Kidney Disease-Mineral and Bone Disorders (CKD-MBD) Market Size By Type (Control Hyperphosphatemia, Maintain Blood Calcium Levels), By Application (Hospital Pharmacies, Retail Pharmacie...

The Global Chronic Kidney Disease-Mineral and Bone Disorders (CKD-MBD) Market was valued at USD 2.1 billion in 2023 and is projected to reach USD 4.0 billion by 2031, growing at a CAGR of 8.3% during the forecast period (2023–2031). The market is being driven by the rising global prevalence of chronic kidney disease (CKD), increasing awareness of complications such as mineral and bone disorders, and advances in diagnostics and treatment modalities. CKD-MBD represents a systemic disorder of mineral and bone metabolism due to CKD, and timely diagnosis and management are critical to reducing associated morbidity and mortality. As nephrology care evolves, the demand for targeted therapies and monitoring tools continues to rise.

Drivers:

Rising Prevalence of Chronic Kidney Disease:

Globally, CKD affects approximately 10% of the population, with a significant proportion of patients at risk of developing CKD-MBD. Increasing rates of diabetes and hypertension—major causes of CKD—are further escalating demand for MBD management solutions.

Advancements in Therapeutic Solutions:

Pharmaceutical innovations such as non-calcium-based phosphate binders, calcimimetics, and vitamin D analogs have expanded therapeutic options. New drugs are improving patient adherence, lowering side effects, and enhancing treatment outcomes.

Improved Diagnostic Techniques:

Enhanced imaging and laboratory diagnostics allow early detection and more accurate monitoring of bone mineral metabolism in CKD patients. These developments are facilitating timely intervention and personalized treatment strategies.

Restraints:

High Cost of CKD-MBD Treatments:

The financial burden of long-term treatment, especially involving biologics and advanced therapies, can limit accessibility—particularly in low- and middle-income countries.

Limited Awareness and Diagnosis:

In many regions, CKD-MBD remains underdiagnosed due to a lack of awareness among both patients and healthcare professionals. This gap delays treatment and negatively impacts prognosis.

Opportunity:

Expanding Geriatric Population:

The aging global population is more susceptible to CKD and related disorders. As healthcare infrastructure improves, particularly in Asia-Pacific and Latin America, the demand for CKD-MBD diagnostics and therapeutics is expected to surge.

Personalized Medicine and Biomarker Development:

Emerging technologies in genomics and biomarker discovery are paving the way for individualized CKD-MBD treatment plans. This personalized approach offers better patient outcomes and minimizes complications.

Market by System Type Insights:

Phosphate Binders accounted for the largest market share in 2023. These drugs remain a cornerstone of CKD-MBD treatment, managing hyperphosphatemia—a key component of the disorder. The demand for non-calcium-based binders is rising due to fewer cardiovascular risks.

Calcimimetics are expected to register the highest CAGR during the forecast period. Their ability to reduce parathyroid hormone levels without increasing calcium or phosphorus makes them a preferred choice for secondary hyperparathyroidism in dialysis patients.

Market by End-use Insights:

Hospitals and Dialysis Centers dominated the market in 2023, comprising over 65% of total revenue. These facilities serve as the primary point of care for CKD patients, especially those in stages 4 and 5, where MBD complications are more pronounced.

Specialty Clinics and Homecare Settings are expected to gain momentum, driven by the shift toward decentralized and personalized care, especially in developed countries where telehealth and remote monitoring tools are widely adopted.

Market by Regional Insights:

North America led the CKD-MBD market in 2023, supported by a robust healthcare system, a high prevalence of CKD, and early adoption of novel therapies.

Asia-Pacific is projected to experience the fastest growth through 2031, fueled by a rapidly aging population, increasing CKD cases, and rising healthcare investments in countries like China and India.

Europe holds a significant share, with high awareness and access to advanced treatment options contributing to steady growth.

Competitive Scenario:

Key players in the Global CKD-MBD Market include AbbVie Inc., Amgen Inc., Sanofi, Vifor Pharma, OPKO Health, Kyowa Kirin Co., Ltd., Akebia Therapeutics, Ardelyx, Inc., and Fresenius Medical Care AG & Co. KGaA. These companies are actively involved in clinical trials, product approvals, and strategic partnerships to expand their presence and improve therapeutic offerings.

Key Market Developments:

In 2024, Amgen launched an updated formulation of its calcimimetic agent for improved patient compliance.

Kyowa Kirin received regulatory approval in 2023 for a new phosphate binder targeting elderly CKD patients with comorbidities.

Fresenius Medical Care integrated AI-based decision tools in dialysis centers to optimize mineral and bone disorder management in real time.

Scope of Work – Global Chronic Kidney Disease-Mineral and Bone Disorders (CKD-MBD) Market

Report Metric Details

Market Size (2023) USD 2.1 Billion

Projected Market Size (2031) USD 4.0 Billion

CAGR (2023–2031) 8.3%

Market Segments By System Type (Phosphate Binders, Calcimimetics, Vitamin D Analogs), By End-use (Hospitals & Dialysis Centers, Specialty Clinics, Homecare)

Growth Drivers Rising CKD prevalence, advancements in diagnostics, growing elderly population

Opportunities Personalized treatment, emerging markets, biomarker-driven therapies

FAQs:

1) What is the current market size of the Chronic Kidney Disease-Mineral and Bone Disorders (CKD-MBD) Market?

The market size was valued at USD 2.1 billion in 2023.

2) What is the major growth driver of the Chronic Kidney Disease-Mineral and Bone Disorders (CKD-MBD) Market?

The major growth driver is the rising global prevalence of chronic kidney disease (CKD) and advancements in CKD-MBD therapeutic solutions.

3) Which is the largest region during the forecast period in the Chronic Kidney Disease-Mineral and Bone Disorders (CKD-MBD) Market?

North America is projected to remain the largest region throughout the forecast period.

4) Which segment accounted for the largest market share in Chronic Kidney Disease-Mineral and Bone Disorders (CKD-MBD) Market?

Phosphate Binders accounted for the largest market share in 2023.

5) Who are the key market players in the Chronic Kidney Disease-Mineral and Bone Disorders (CKD-MBD) Market?

Key players include Amgen Inc., Sanofi, AbbVie Inc., Kyowa Kirin Co., Ltd., Fresenius Medical Care, and Vifor Pharma.